INOVIO is focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases. In the last several years INOVIO has had its data published in several prominent peer-reviewed medical journals including:
The Journal of Infectious Diseases
January 2022
Open Forum Infectious Diseases
December 2021
Nature Communications
May 2020
The Lancet Infectious Diseases
July 2019
Filter by Category
Title | Disease Target | Product |
---|---|---|
CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens
Molecular Therapy — March 2020 |
Disease TargetPSA | ProductINO-5151 |
Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT
Molecular Therapy — November 2017 |
Disease TargethTERT | ProductINO-5401 |
A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity
Molecular Therapy — February 2017 |
Disease TargetWT1 | ProductINO-5401 |
Highly Optimized DNA Vaccine Targeting Human Telomerase Reverse Transcriptase Stimulates Potent Antitumor Immunity
Cancer Immunology Research — September 2013 |
Disease TargethTERT | ProductINO-5401 |
Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses
Human Vaccines — January 2011 |
Disease TargetPSA, PSMA | ProductINO-5401 |
Title | Disease Target | Product |
---|---|---|
DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity
JCI Insight — April 2019 |
Disease TargetHER2 |
Title | Disease Target | Product |
---|---|---|
Integration of needle-free jet injection with advanced electroporation delivery enhances the magnitude, kinetics, and persistence of engineered DNA vaccine induced immune responses
Vaccine — June 2019 |
Disease TargetDelivery | ProductCELLECTRA |
A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle
Vaccine — September 2011 |
Disease TargetDelivery | ProductCELLECTRA |
Title | Disease Target | Product |
---|---|---|
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial
The Journal of Infectious Diseases — January 2022 |
Disease TargetCOVID-19 | ProductINO-4800 |
571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster
Open Forum Infectious Diseases — December 2021 |
Disease TargetCOVID-19 | ProductINO-4800 |
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants
npj Vaccines — October 2021 |
Disease TargetCOVID-19 | ProductINO-4800 |
Immunogenicity of a DNA vaccine candidate for COVID-19
Nature Communications — May 2020 |
Disease TargetCOVID-19 | ProductINO-4800 |
© Copyright 2023 INOVIO Pharmaceuticals. All rights reserved.